Nalbantoğlu Mecbure, Altunrende Burcu, Tunçer Özlem Güngör, Akman Gülşen
Neurology Department, İstanbul Bilim University Faculty of Medicine, İstanbul, Turkey.
Noro Psikiyatr Ars. 2019 Aug 16;58(2):163-165. doi: 10.29399/npa.23353. eCollection 2021 Jun.
In recent years, by the usage of new immune therapeutic agents for cancer treatment, the neurologic adverse events began to be seen more frequently. Nivolumab, one of the immune checkpoint inhibitor, is a human IgG4 antibody that blocks programmed cell death protein 1 and is approved against metastatic melanoma, squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma after failure of prior line of chemotherapy. Here, we present a 40-year-old patient developing encephalopathy after treatment of Hodgkin's lymphoma with the immune checkpoint inhibitor nivolumab. In literature, cases of autoimmune encephalitis after receiving combination therapy of immune checkpoint inhibitors ipilimumab and nivolumab were described before. As far as we know, this is the unique case of encephalopathy reported after monotherapy with nivolumab treatment used for Hodgkin's lymphoma.
近年来，随着新型免疫治疗药物用于癌症治疗，神经系统不良事件开始更频繁地出现。纳武单抗是一种免疫检查点抑制剂，它是一种人IgG4抗体，可阻断程序性细胞死亡蛋白1，已被批准用于治疗先前一线化疗失败后的转移性黑色素瘤、鳞状细胞肺癌、肾细胞癌和霍奇金淋巴瘤。在此，我们报告一名40岁患者，在用免疫检查点抑制剂纳武单抗治疗霍奇金淋巴瘤后发生脑病。在文献中，之前曾描述过接受免疫检查点抑制剂伊匹单抗和纳武单抗联合治疗后发生自身免疫性脑炎的病例。据我们所知，这是首例报告的在用纳武单抗单药治疗霍奇金淋巴瘤后发生脑病的病例。
